Nova Leap Health (NLH) Q4 2024 earnings summary

Executive summary

• Achieved record Adjusted EBITDA for the second consecutive year, reaching $1.56M in 2024, up 5.7% year-over-year.

• Operating income for 2024 rose 87.7% to $863,712 compared to 2023.

• Net income in Q4 2024 was $886,268, reversing losses from both Q3 2024 and Q4 2023.

Financial highlights

• 2024 revenues were $25.76M, a 1.6% decrease from 2023; Q4 2024 revenues were $6.59M, up 2.8% sequentially.

• Gross profit margin improved to 38.4% in 2024 from 37.3% in 2023; Q4 2024 margin was 39.1%.

• Cash and cash equivalents at year-end were $1.40M, up $508,002 for the year.

Outlook and guidance

• Forward-looking statements highlight plans for future acquisitions, business growth, and anticipated improvements in annualized revenue and Adjusted EBITDA margins.